Companies Alaunos Therapeutics, Inc.
Alaunos Therapeutics (TCRT): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Email me Alaunos Therapeutics, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $48,153FY2023
- $308,344FY2024
CEO total pay was $308,344 in fiscal 2024, up from $48,153 in fiscal 2023.
FY2024: salary $233,974 · bonus $0 · stock awards $0 · option awards $59,880
Order TCRT
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Melinda Lackey | $0 | $0 | $0 | $3,087 | $0 | $0 | $427,283 | $430,370 |
| Legal & Administration, Corporate Secretary | ||||||||
| Kevin Boyle | 317,500 | 0 | 0 | 0 | 0 | 0 | 75,000 | 392,500 |
| Former Chief Executive Officer | ||||||||
| Dale Hogue | 233,974 | 0 | 0 | 59,880 | 0 | 0 | 14,490 | 308,344 |
| Interim Chief Executive Officer | ||||||||
| Ferdinand Groenewald | 0 | 0 | 0 | 3,087 | 0 | 0 | 159,217 | 162,304 |
| Vice President, Finance | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Melinda Lackey | $430,370 | $831,737 | $764,743 | ↓ −401,367 |
| Kevin Boyle | 392,500 | 1,986,946 | — | ↓ −1,594,446 |
| Dale Hogue | 308,344 | 48,153 | — | ↑ +260,191 |
| Ferdinand Groenewald | 162,304 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company uses base salaries to recognize experience, skills, and responsibilities, reviewing them annually to align with market levels. Long-term equity incentive compensation, specifically stock options, is considered a critical component to link executive interests with stockholders and incentivize performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer and Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Dale Hogue | Option | 334 | 18 | — |
| Melinda Lackey | Option | 540 | 315 | — |
| Melinda Lackey | Option | 617 | 183 | — |
| Dale Hogue | Option | 667 | 10.5 | — |
| Melinda Lackey | Option | 750 | 75 | — |
| Ferdinand Groenewald | Option | 1,406 | 2.42 | — |
| Melinda Lackey | Option | 1,406 | 2.42 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Holger WeisIndependent · Audit · Compensation | $109,000 | $0 | $23,090 | — | — | $132,090 |
| Robert W. PostmaIndependent · Audit · Compensation · Corporate Governance and Nominating | 81,000 | 0 | 2,441 | — | — | 93,441 |
| Robert J. HofmeisterIndependent · Compensation · Corporate Governance and Nominating | 71,000 | 0 | 12,815 | — | — | 83,815 |
| Jaime VieserIndependent · Audit · Corporate Governance and Nominating | 68,000 | 0 | 12,815 | — | — | 80,815 |
| Dale Curtis HogueIndependent | 2,740 | 0 | 0 | — | — | 2,740 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | $150,000 |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $331,740 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $331,740 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Alaunos Therapeutics as a peer
Companies that benchmark against TCRT
No companies currently name TCRT as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Alaunos Therapeutics, Inc. | 2024 | Dale Hogue | $233,974 | $0 | $59,880 | $0 | $308,344 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-07-03 | 232,638 | 144,957 | 3,566 | 61.61% | Passed |
| 2024 | 2024-06-06 | 1,851,846 | 1,032,789 | 85,111 | 64.2% | Passed |
| 2023 | 2023-06-06 | 85,893,572 | 20,980,848 | 1,948,700 | 78.93% | Passed |
| 2022 | 2022-06-13 | 88,627,065 | 7,777,874 | 5,651,319 | 91.93% | Passed |
| 2021 | 2021-05-19 | 98,887,173 | 6,555,935 | 464,677 | 93.78% | Passed |
| 2019 | 2019-06-13 | 47,148,496 | 3,829,194 | 455,171 | 91.67% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-07-03 | 61.61%a |
| 2024 | 2024-06-06 | 64.2%b |
| 2023 | 2023-06-06 | 78.93%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions will have the same effect as Against votes on Proposal 2, Proposal 3, the Reverse Stock Split Proposal, the Authorized Stock Increase Proposal and the Adjournment Proposal, and will have no effect on Proposals 1 and 4.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (15 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Melinda Lackey. DEF 14A, filed 2025-05-21. Section “Summary Compensation Table”. As printed: 430,370. View filing ↗
- Section 01, Kevin Boyle. DEF 14A, filed 2025-05-21. Section “Summary Compensation Table”. As printed: 392,500. View filing ↗
- Section 01, Dale Hogue. DEF 14A, filed 2025-05-21. Section “Summary Compensation Table”. As printed: 308,344. View filing ↗
- Section 01, Ferdinand Groenewald. DEF 14A, filed 2025-05-21. Section “Summary Compensation Table”. As printed: 162,304. View filing ↗
- Section 08, Holger Weis. DEF 14A, filed 2025-05-21. Section “Director Compensation”. As printed: 132,090. View filing ↗
- Section 08, Robert W. Postma. DEF 14A, filed 2025-05-21. Section “Director Compensation”. As printed: 93,441. View filing ↗
- Section 08, Robert J. Hofmeister. DEF 14A, filed 2025-05-21. Section “Director Compensation”. As printed: 83,815. View filing ↗
- Section 08, Jaime Vieser. DEF 14A, filed 2025-05-21. Section “Director Compensation”. As printed: 80,815. View filing ↗
- Section 08, Dale Curtis Hogue. DEF 14A, filed 2025-05-21. Section “Director Compensation”. As printed: 2,740. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-07-10. Item 5.07 · say-on-pay result. As reported: 61.61% (votes for as printed: 232,638). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-12. Item 5.07 · say-on-pay result. As reported: 64.2% (votes for as printed: 1,851,846). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-12. Item 5.07 · say-on-pay result. As reported: 78.93% (votes for as printed: 85,893,572). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 331,740 + equity 0 + all other 0 = 331,740, summed across the director compensation table rows.
- Alaunos Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-05-21. CEO total compensation as printed in Alaunos Therapeutics, Inc.'s own proxy. As printed: 308,344. View filing ↗